Autologous stem cell transplantation for small cell lung cencer

Biology of Blood and Marrow Transplantation

Volumn 8, Issue 5, 2002, Pages 273-280

  Rizzo, J Douglas ^a   Elias, Anthony D ^a   Stiff, Patrick J ^a   Lazarus, Hillard M ^a   Zhang, Mei Jie ^a   Oblon, David J ^a   Pecora, Andrew L ^a   Hale, Gregory A ^a   Horowitz, Mary M ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Autologous stem cell transplantation; Small cell lung cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; ETOPOSIDE; GROWTH FACTOR; IFOSFAMIDE; PACLITAXEL; PLATINUM DERIVATIVE;

ADULT; AGED; ARTICLE; AUTOTRANSPLANTATION; BONE MARROW; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER LOCALIZATION; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PERIPHERAL BLOOD STEM CELL; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 0036276301     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1053/bbmt.2002.v8.pm12064365     Document Type: Article

References (40)

1. Cancer statistics, 2000
2. Therapy of small cell lung cancer: A perspective on two decades of clinical research
3. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide
4. Long-term disease-free survival in small-cell carcinoma of the lung: A study of clinical determinants
5. Ten-year follow-up of Southwest Oncology Group 8269: A phase II trial of concomitant cisplatin-etoposide and daily thoracic radiotherapy in limited small-cell lung cancer
6. Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine
7. Intensive chemotherapy of small cell bronchogenic carcinoma
8. Treatment of extensive stage small cell bronchogenic carcinoma: Effects of variation in intensity of induction chemotherapy
9. A randomized comparison of high dose versus conventional dose cyclophosphamide, doxorubicin, and vincristine for extensive stage small cell lung cancer: A phase III trial of the Southeastern Cancer Study Group
10. High-dose cyclophosphamide in the induction therapy of small cell lung cancer: Minor improvements in rate of remission and survival
11. Co-trimoxazole prophylaxis during high-dose chemotherapy of small-cell lung cancer
12. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer
13. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer
14. Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: A randomized study
15. Intensive combined modality therapy for limited stage small cell lung cancer
16. Dose intensive therapy in lung cancer
17. Dose-intensive therapy for limited-stage small-cell lung cancer: Long-term outcome
18. Nonparametric estimation from incomplete observations
19. Regression analysis and life tables
20. Testing for center effects in multicenter survival studies: A Monte Carlo comparison of fixed and random effects
21. High-dose combined-modality therapy and autologous bone marrow transplantation in resistant cancer
22. Phase I trial of high-dose etoposide, high-dose cisplatin, and reinfusion of autologous bone marrow for lung cancer
23. Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC #4366650 and cryopreserved autologous marrow transplantation for refractory cancer: A phase I-II study
24. High-dose VP-16-213 and autologous bone marrow transplantation for refractory malignancies: A phase I study
25. High-dose etoposide with autologous bone marrow transplantation as initial treatment of small cell lung cancer: A negative report
26. Multiple courses of high-dose ifosfamide, carboplatin, and etoposide with peripheral-blood progenitor cells and filgrastim for small-cell lung cancer: A feasibility study by the European Group for Blood and Marrow Transplantation
27. A phase I dose escalation study of multicyclic, dose-intensive chemotherapy with peripheral blood stem cell support for small cell lung cancer
28. High-dose ifosfamide, carboplatin, and etoposide with autologous peripheral blood progenitor cell transplantation for small-cell lung cancer
29. Sequential high dose chemotherapy with filgrastim/peripheral stem cell support in extensive stage small cell lung cancer
30. Treatment intensification which includes high dose induction improves survival of lung carcinoma patients treated by high dose chemotherapy with hematopoietic progenitor cell rescue but does not prevent high rate of relapses
31. Hematopoietic stem cell transplantation for small cell lung cancer
32. Multimodality treatment including early high-dose chemotherapy with peripheral blood stem cell transplantation in limited-disease small cell lung cancer
33. Thoracic radiotherapy variables: Influence on local control in small cell lung cancer limited disease
34. Long-term survival in small-cell lung cancer: Posttreatment characteristics in patients surviving 5 to 18+ years: An analysis of 1,714 consecutive patients
35. Analysis of prognostic factors in 766 patients with small cell lung cancer (SCLC): The role of sex as a predictor for survival
36. An overview of prognostic factors in small cell lung cancer: A report from the subcommittee for the management of lung cancer of the United Kingdom Coordinating Committee on Cancer Research
37. Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 100 patients with small-cell lung cancer: A mature follow-up report